AstraZeneca And Abbott Pull The Plug On Cardio Combination Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
Saying it was no longer commercially attractive, the partners ended development of mixed dyslipidemia treatment Certriad, a pill that combines a statin and a fibrate, due to the FDA's "complete response" received earlier this year.
You may also be interested in...
New Cholesterol Guidelines Follow Long History Of Failed Outcomes Trials
The cardiology community is increasingly questioning the value of adding on a variety of lipid therapies to treatment with highly effective statins, based on accumulating evidence of the lack of value of affecting cholesterol parameters other than LDL.
Abbott Refreshes Rheumatoid Arthritis Strategy By Licensing Biotest's Phase II Candidate
For $85 million up-front in a deal potentially worth $480 million, Abbott gets a mid-stage antibody that could be a possible successor to strong-selling Humira.
Abbott Refreshes Rheumatoid Arthritis Strategy By Licensing Biotest's Phase II Candidate
For $85 million up-front in a deal potentially worth $480 million, Abbott gets a mid-stage antibody that could be a possible successor to strong-selling Humira.